FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2008018265> ?p ?o ?g. }

• W2008018265 endingPage "939" @default.
• W2008018265 startingPage "934" @default.
• W2008018265 abstract "Recent advances in allogeneic stem cell transplantation (allo-HSCT) have included the advent of reduced-intensity conditioning (RIC) regimens to decrease the toxicity of myeloablative allo-SCT and the use of double umbilical cord blood (dUCB) units as a graft source in adults lacking a suitable donor. The FB2A2 regimen (fludarabine 30 mg/kg/day for 5-6 days + i.v. busulfan 3.6 mg/kg/day for 2 days + rabbit antithymocyte globulin 2.5 mg/kg/day for 2 days) supported by peripheral blood stem cells (PBSCs) and the TCF regimen (fludarabine 200 mg/m² for 5 days + cyclophosphamide 50 mg/kg for 1 day + low-dose [2 Gy] total body irradiation) supported by dUCB units are currently the most widely used RIC regimens in many centers and could be considered standard of care in adults eligible for an RIC allo-SCT. Here we compared, retrospectively, the outcomes of adults patients who received the FB2A2-PBSC RIC regimen (n = 52; median age, 59 years; median follow-up, 19 months) and those who received the dUCB-TCF RIC regimen (n = 39; median age, 56 years; median follow-up, 20 months) for allo-SCT between January 2007 and November 2010. There were no significant between-group differences in patient and disease characteristics. Cumulative incidences of engraftment, acute grade II-IV and chronic graft-versus-host disease were similar in the 2 groups. The median time to platelet recovery, incidence of early death (before day +100), and 2-year nonrelapse mortality were significantly higher in the dUCB-TCF group (38 days versus 0 days [P <.0001]; 20.5% versus 4% [P = .05], and 26.5% versus 6% [P = .02], respectively). The groups did not differ in terms of 2-year overall survival (62% for FB2A2-PBSC versus 61% for dUCB-TCF), disease-free survival (59% versus 50.5%), or relapse incidence (35.5% versus 23%). In multivariate analysis, the presence of a lymphoid disorder was associated with a significantly higher 2-year overall survival (hazard ratio, 0.42; 95% confidence interval, 0.20-0.87; P = .02), whereas patients receiving a FB2A2-PBSC allo-SCT had a significantly lower 2-year nonrelapse mortality (hazard ratio, 0.24; 95% confidence interval, 0.1-0.7; P = .01). There were no factors associated with higher 2-year disease-free survival or lower relapse incidence. This study suggests that the dUCB-TCF regimen provides a valid alternative in adults lacking a suitable donor and eligible for RIC allo-SCT. Prospective and randomized studies are warranted to establish the definitive role of dUCB RIC allo-SCT in adults. In addition, strategies for decreasing nonrelapse mortality after dUCB RIC allo-SCT are urgently needed." @default.
• W2008018265 created "2016-06-24" @default.
• W2008018265 creator A5007623289 @default.
• W2008018265 creator A5007731800 @default.
• W2008018265 creator A5011154715 @default.
• W2008018265 creator A5011827756 @default.
• W2008018265 creator A5020996390 @default.
• W2008018265 creator A5023982618 @default.
• W2008018265 creator A5036207495 @default.
• W2008018265 creator A5039191979 @default.
• W2008018265 creator A5041434329 @default.
• W2008018265 creator A5041517974 @default.
• W2008018265 creator A5043743398 @default.
• W2008018265 creator A5047145227 @default.
• W2008018265 creator A5054214593 @default.
• W2008018265 creator A5065205435 @default.
• W2008018265 creator A5068144072 @default.
• W2008018265 creator A5077603727 @default.
• W2008018265 creator A5078123316 @default.
• W2008018265 creator A5081625864 @default.
• W2008018265 date "2013-06-01" @default.
• W2008018265 modified "2023-10-17" @default.
• W2008018265 title "Comparison of Outcomes after Two Standards-of-Care Reduced-Intensity Conditioning Regimens and Two Different Graft Sources for Allogeneic Stem Cell Transplantation in Adults with Hematologic Diseases: A Single-Center Analysis" @default.
• W2008018265 cites W1483338207 @default.
• W2008018265 cites W1530764705 @default.
• W2008018265 cites W1965613868 @default.
• W2008018265 cites W1973617793 @default.
• W2008018265 cites W1977316053 @default.
• W2008018265 cites W1981025559 @default.
• W2008018265 cites W1988769943 @default.
• W2008018265 cites W1989062213 @default.
• W2008018265 cites W2003112911 @default.
• W2008018265 cites W2011561948 @default.
• W2008018265 cites W2018953748 @default.
• W2008018265 cites W2030065696 @default.
• W2008018265 cites W2030225848 @default.
• W2008018265 cites W2034333555 @default.
• W2008018265 cites W2053278212 @default.
• W2008018265 cites W2058846777 @default.
• W2008018265 cites W2069056227 @default.
• W2008018265 cites W2069209063 @default.
• W2008018265 cites W2075355471 @default.
• W2008018265 cites W2080878594 @default.
• W2008018265 cites W2081698207 @default.
• W2008018265 cites W2085600578 @default.
• W2008018265 cites W2086337992 @default.
• W2008018265 cites W2090051716 @default.
• W2008018265 cites W2091110059 @default.
• W2008018265 cites W2092726587 @default.
• W2008018265 cites W2099847697 @default.
• W2008018265 cites W2122469298 @default.
• W2008018265 cites W2133201432 @default.
• W2008018265 cites W2134823742 @default.
• W2008018265 cites W2135067231 @default.
• W2008018265 cites W2138794212 @default.
• W2008018265 cites W2140198443 @default.
• W2008018265 cites W2152197116 @default.
• W2008018265 cites W2163821792 @default.
• W2008018265 cites W2164273932 @default.
• W2008018265 cites W2318851296 @default.
• W2008018265 cites W2517567208 @default.
• W2008018265 cites W2980219441 @default.
• W2008018265 cites W4246085869 @default.
• W2008018265 doi "https://doi.org/10.1016/j.bbmt.2013.03.009" @default.
• W2008018265 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23523970" @default.
• W2008018265 hasPublicationYear "2013" @default.
• W2008018265 type Work @default.
• W2008018265 sameAs 2008018265 @default.
• W2008018265 citedByCount "22" @default.
• W2008018265 countsByYear W20080182652013 @default.
• W2008018265 countsByYear W20080182652014 @default.
• W2008018265 countsByYear W20080182652015 @default.
• W2008018265 countsByYear W20080182652016 @default.
• W2008018265 countsByYear W20080182652017 @default.
• W2008018265 countsByYear W20080182652018 @default.
• W2008018265 countsByYear W20080182652021 @default.
• W2008018265 countsByYear W20080182652023 @default.
• W2008018265 crossrefType "journal-article" @default.
• W2008018265 hasAuthorship W2008018265A5007623289 @default.
• W2008018265 hasAuthorship W2008018265A5007731800 @default.
• W2008018265 hasAuthorship W2008018265A5011154715 @default.
• W2008018265 hasAuthorship W2008018265A5011827756 @default.
• W2008018265 hasAuthorship W2008018265A5020996390 @default.
• W2008018265 hasAuthorship W2008018265A5023982618 @default.
• W2008018265 hasAuthorship W2008018265A5036207495 @default.
• W2008018265 hasAuthorship W2008018265A5039191979 @default.
• W2008018265 hasAuthorship W2008018265A5041434329 @default.
• W2008018265 hasAuthorship W2008018265A5041517974 @default.
• W2008018265 hasAuthorship W2008018265A5043743398 @default.
• W2008018265 hasAuthorship W2008018265A5047145227 @default.
• W2008018265 hasAuthorship W2008018265A5054214593 @default.
• W2008018265 hasAuthorship W2008018265A5065205435 @default.
• W2008018265 hasAuthorship W2008018265A5068144072 @default.
• W2008018265 hasAuthorship W2008018265A5077603727 @default.
• W2008018265 hasAuthorship W2008018265A5078123316 @default.
• W2008018265 hasAuthorship W2008018265A5081625864 @default.
• W2008018265 hasBestOaLocation W20080182651 @default.
• W2008018265 hasConcept C126322002 @default.

• next